Clinical Trial · NCT05260606

Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer

Overview

1. Hypothesis : imaging biomarkers of tumor measured by F-18 fluorodeoxyglucose (FDG) positron emission tomography(PET)/computed tomography(CT) is correlated with immune checkpoint inhibitor (ICI) treatment response and patient prognosis. 2. Purpose: To evaluate the association between metabolic imaging parameters measured by F-18 FDG PET/CT and clinical outcomes in patients with non-small cell lung cancer treated with ICIs. 3. Study subject: patients with non-small cell lung cancer who will be treated with ICIs. 4. Study design: prospective observational study 5. Intervention: F-18 FDG PET/CT

Sponsor

Samsung Medical Center

Contacts

Seung hwan Moon, M.D., Ph.D. (CONTACT)

seunghwan.moons.moon@samsung.com

+82-2-3410-6293

hoyun lee, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05260606

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

pathologically proven non-small cell lung cancer: adenocarcinoma or squamous cell carcinoma
ECOG performance status ≤ 2
patients to be treated with immune checkpoint inhibitors (nivolumab or pembrolizumab or atezolizumab)

Exclusion

subjects with uncontrolled diabetes
subjects with severe uncontrolled infection
subjects without measurable lesion: They must have at least one measurable lesion with a diameter of 10 mm by spiral CT or multi-detector CT (MD CT) or 20 mm or larger by conventional CT.